Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus

About this update from Eupraxia Pharmaceuticals, Inc.

[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n June 15, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) today announced that it has filed and obtained a receipt for a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces of\n \n Canada\n \n , except Québec.\n \n \n Upon a final short form base shelf prospectus (the \"Prospectus\") becoming effective, replacing the Company's existing shelf prospectus filed in\n \n January 2022\n \n , these filings, subject to securities regulatory requirements, will allow the Company and certain of its securityholders to qualify the distribution of up to\n \n C$200 million\n \n of common shares, preferred shares, debt securities, warrants, subscription receipts, and units, or any combination thereof (collectively, the \"Securities\") during the 25-month period that the Prospectus is effective, in amounts, at prices and on terms based on market conditions at the time of any offering, and set forth in an accompanying shelf prospectus supplement (\"Prospectus Supplement\").\n \n \n The filing of the Prospectus is intended to provide the Company with financing flexibility. Each Prospectus Supplement will contain specific information concerning, among other matters, the Securities to be issued and the use of proceeds from any such issuance. There is no certainty that any Securities will be offered or sold under the Prospectus and any Prospectus Supplement within the 25-month period that it is effective.\n \n \n This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualifications under the securities laws of any such jurisdiction.\n \n \n \n About Eupraxia Pharmaceuticals Inc.\...

More updates from Eupraxia Pharmaceuticals, Inc.